IDEAL_ANSWER:
- Kymriahâ„¢ has been approved for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia.

EXACT_ANSWER:
- children and young adults with refractory or relapse B cell precursor acute lymphoblastic leukemia